|
業務類別
|
Biotechnology |
|
業務概覽
|
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates. |
| 公司地址
| 1901 West 47th Place, Kansas, KS, USA, 66205 |
| 電話號碼
| +1 913 942-2300 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cingulate.com |
| 員工數量
| 14 |
| Dr. Shane J. Schaffer, Pharm.D. |
Chief Executive Officer and Director |
美元 479.53K |
29/05/2026 |
| Dr. Raul R. Silva, M.D. |
Executive Vice President and Chief Science Officer |
-- |
29/05/2026 |
| Dr. Matthew N. Brams, M.D. |
Executive Vice President and Chief Medical Officer |
美元 165.00K |
29/05/2026 |
| Ms. Jennifer L. Callahan |
Executive Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 373.00K |
29/05/2026 |
| Mr. Nilay Dahyabhai Patel |
Executive Vice President and Chief Compliance Officer |
美元 230.48K |
23/07/2026 |
| Mr. Bryan Wade Downey |
Executive Vice President and Chief Commercial Officer |
-- |
29/05/2026 |
|
|
| Dr. Shane J. Schaffer, Pharm.D. |
Chief Executive Officer and Director |
29/05/2026 |
| Mr. Jeff Hargroves |
Independent Director |
19/05/2026 |
| Mr. Peter J. Werth |
Independent Director |
29/05/2026 |
| Mr. Bryan Lawrence |
Independent Director |
29/05/2026 |
| Mr. Zhanpeng Frederick Jiang |
Independent Director |
02/04/2026 |
|
|
|
|
